Lozano-Rodríguez Carlos Alfredo1 ; Rodríguez-Matías Venus Alexandra1 ; Real-Cotto Jhony Joe2 & Jaramillo-Feijoo Leyda Elizabeth2
La correspondencia debe dirigirse a Jhony Real Cotto. Email: email@example.com
Recibido el 10 de Noviembre del 2019. Aceptado el 13 de Enero de 2020
LOZANO, C.; RODRÍGUEZ, V.; REAL, J. & JARAMILLO, L. Breast cancer and its response to neoadjuvant treatment according to molecular subtype. J. health med. sci., 6(1):21-27, 2020.
ABSTRACT: Breast cancer is one of the most frequent pathologies worldwide and in Ecuador it occupies an important place in mortality. In patients with advanced stage tumors, the neo-adjuvant chemotherapy is the indicated procedure to achieve a satisfactory tumor reduction. The aim was to determine the clinical and pathological response in patients with breast cancer treated with neoadjuvant chemotherapy according to each molecular subtype, treated at the “Teodoro Maldonado Carbo” hospital in the period 2015 to 2017. We used a non-experimental, crosssectional type design. Patients with breast cancer who received neoadjuvant, mostly with chemotherapy based on anthracyclines and taxanes. The patients were classified by their molecular subtypes, they were obtained based on the immunohistochemical characteristics of the pathology reports that appear in the AS-400 system. The clinical response to treatment was checked using the RECIST 1.1 Criteria. As a result, a sum of 171 patients were analyzed. The average age of the patients was 55 + 13 years old; 25% were luminal B (Her +), 24% luminal B (Her-), 22% triple negative, 18% Her2 + and 12% luminal A; 52% of the patients had stage III of the disease; 75% (129) of the patients underwent a modified radical mastectomy. As a conclusion, the complete pathological response in patients with neoadjuvant treatment is related to molecular subtypes and this is statistically significant. Also, the highest rates of complete pathological response in the molecular groups of Her2 + and triple negative were evident.
KEY WORDS: breast cancer; molecular subtype; neoadjuvant chemotherapy; receivers; estrogen; progesterone.
Dirección para correspondencia:
Jhony Real Cotto
Departamento de Bioestadística SOLCA –Guayaquil
Av. Pedro Menéndez Gilbert y calle Atahualpa, Parroquia Tarqui